Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Cardinal Health Inc    CAH

Delayed Quote. Delayed  - 08/26 10:02:02 pm
79.35 USD   -0.01%
08/18 CARDINAL HEALTH : Coalition awarded $25,000 grant
08/08 CARDINAL HEALTH : William Blair Analysts Decrease Earnings Estimates..
08/08 CARDINAL HEALTH : Board of Directors Approves Quarterly Dividend
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Cardinal to Buy Home-Medical Firm AssuraMed for $2.07 Billion

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/14/2013 | 02:26pm CEST

By Jon Kamp

--Cardinal paying $2.07 billion to tap growing home-care market

--Deal adds to Cardinal's existing medical-supplies franchise

--Cardinal sees earnings benefit from fast-growing AssuraMed

Drug wholesaler and medical-products company Cardinal Health Inc. (>> Cardinal Health, Inc.) said Thursday it will acquire closely held medical-supplier AssuraMed for $2.07 billion to reach into a growing home-care market.

AssuraMed currently serves more than one million patients nationally with more than 30,000 products, including supplies for respiratory issues, incontinence and diabetes. The company bought Invacare Corp.'s (>> Invacare Corporation) domestic medical-supplies business for $150 million last month. Including that business, Cardinal Heath said AssuraMed had 2012 revenue of $1 billion.

Cardinal cited government data showing this market growing sales at a 7%-and-rising clip, but said AssuraMed has historically grown at more than twice that pace. Though AssuraMed will represent only about 1% of total Cardinal sales, it has higher profit margins, and Cardinal expects an earnings benefit.

Dublin, Ohio's Cardinal gets most of its sales from a pharmaceutical business that includes drug distribution. Cardinal also has a medical segment that distributes an array of medical, surgical and lab products, but is focused today on hospitals and other professional customers.

The AssuraMed deal will extend Cardinal into growing home-care market fueled by aging baby boomers and health payers--from the government to private insurers--looking for cost effective ways to manage patients with chronic illness or on-the-mend from accidents and surgery.

"The general gravitational pull is toward more care moving toward the home," said George Barrett, Cardinal's chairman and chief executive, in an interview.

Cardinal shares rose 2.1% to $46.38 in recent trading. They are up nearly 13% so far this year.

Mr. Barrett believes the home-health business will help Cardinal's relationship with existing customers, since the health system is shifting toward rewarding health providers for patient outcomes, rather than the volume of service provided. This can mean caregivers taking on more responsibility for patients as they move from hospitals to rehabilitation centers or their own homes.

The deal "connects to the dialogue that we're having with our partners," Mr. Barrett said in an interview. It "makes us a more relevant strategic partner to them."

Cardinal said AssuraMed leads a fragmented, roughly $16 billion market for the products it supplies. The company is split into two main businesses: a wholesale distributor that sends products to commercial customers, such as home medical-equipment suppliers, and another business that ships directly to patients' homes.

Cardinal expects the deal to add two cents to three cents a share to its fiscal 2013 adjusted earnings, assuming the deal closes by early April. The company also estimates its will boost fiscal 2014 adjusted earnings by at least 18 cents a share.

Additionally, Cardinal expects at least $50 million in deal-related savings by 2016, and for growing savings thereafter.

Cardinal is financing the deal with $1.3 billion in new senior, unsecured notes and cash. Debt-ratings firm Fitch Ratings called the transaction "strategically sound" while saying it should bolster Cardinal's intermediate-term growth outlook.

The medical-products deal comes as Cardinal faces some big questions in its drug wholesale business. The company is working to try and keep its two biggest customers, the drugstore chains CVS Caremark Corp. (>> CVS Caremark Corporation) and Walgreen Co. (>> Walgreen Company), after existing contracts with both companies end this summer.

--Melodie Warner contributed to this article.

Write to Jon Kamp at jon.kamp@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CARDINAL HEALTH INC
08/18 CARDINAL HEALTH : The Conference Board Elects New Vice Chair
08/18 CARDINAL HEALTH : Coalition awarded $25,000 grant
08/08 CARDINAL HEALTH : William Blair Analysts Decrease Earnings Estimates for Cardina..
08/08 CARDINAL HEALTH : Board of Directors Approves Quarterly Dividend
08/02DJCARDINAL HEALTH : Warns of Quarterly Profit Decline
08/02DJCARDINAL HEALTH : Warns of Quarterly Profit Decline
08/02 CARDINAL HEALTH : beats Street 4Q forecasts
08/02 CARDINAL HEALTH : Reports Q4 And Fiscal 2016 Results, Provides Fiscal 2017 Outlo..
08/02 CARDINAL HEALTH INC : Results of Operations and Financial Condition (form 8-K)
07/29 ACCELERATING THE RATE OF CHANGE IN H : Cardinal Health Foundation Announces Pati..
More news
Sector news : Drug Retailers - NEC
08/22DJSINOPHARM GROUP : 1st Half Net Profit CNY2.53 Billion, Up 32% on Year
08/17DJTarget Dims Outlook as Sales Struggle
08/09DJPatient Survey Company Press Ganey to Sell Itself to Swedish Firm EQT
08/09DJValeant Posts a Loss and Says It Will Retool
08/05DJAbbVie Sues Amgen Over Humira
More sector news : Drug Retailers - NEC
News from SeekingAlpha
08/27 Bert's August Stock Watch List
08/25 88 Stock Picks For The Next 30 Years (Or More)
08/25 The 3 Worst Performing Dividend Aristocrats This Year
08/24 DIVIDEND GROWTH INVESTING : Looking To The S&P500 For Clarity
08/22 PREMIER DIVIDEND GROWTH STOCKS : Is There Any Value? A Sector By Sector Summary ..
Advertisement
Financials ($)
Sales 2017 131 298 M
EBIT 2017 2 993 M
Net income 2017 1 544 M
Debt 2017 2 275 M
Yield 2017 1,98%
P/E ratio 2017 16,31
P/E ratio 2018 14,34
EV / Sales 2017 0,21x
EV / Sales 2018 0,19x
Capitalization 25 280 M
More Financials
Chart CARDINAL HEALTH INC
Duration : Period :
Cardinal Health Inc Technical Analysis Chart | CAH | US14149Y1082 | 4-Traders
Full-screen chart
Technical analysis trends CARDINAL HEALTH INC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 93,9 $
Spread / Average Target 18%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
George S. Barrett Chairman & Chief Executive Officer
Michael C. Kaufmann Chief Financial Officer
Patricia B. Morrison Chief Information Officer
Calvin Ramarro Darden Independent Director
Gregory B. Kenny Lead Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CARDINAL HEALTH INC-11.11%25 280
CVS HEALTH CORP-4.61%99 435
WALGREENS BOOTS ALLIAN..-6.77%85 925
EXPRESS SCRIPTS HOLDIN..-17.27%45 571
MCKESSON CORPORATION-7.32%41 256
AMERISOURCEBERGEN CORP..-17.32%18 413
More Results